(Updated January 4, 2021)
The United States and countries around the world face a major public health concern with the current outbreak of the novel (new) coronavirus (COVID-19). In an effort to serve its members, ASH is maintaining this webpage as a medium to exchange information to assist hematologists in navigating the COVID-19 public health crisis.
While ASH aims to provide a forum for the exchange of information that is helpful, accurate and up-to-date, the relevant health information and data concerning the disease, as well as the various governmental actions and responses to the disease, are changing constantly, and ASH makes no representation, warranty, or guaranty whatsoever as to any information that may be exchanged through this webpage.
It remains the responsibility of each medical professional to decide on the appropriate medical advice, diagnosis, and treatment for patients. In rendering such advice, please bear in mind that although ASH attempts to include on this page information from reliable sources, it has not conducted a substantive review of each item posted below, nor does it have access to sufficient information to police potential conflicts of interest. Particularly given the exigencies presented by the current COVID-19 pandemic, we urge you to assist us identifying information that has been particularly helpful to you so that we might more prominently feature it, as well as any information that is inaccurate, outdated or inappropriate so that we can remove it.
- Frequently Asked Clinical Questions about COVID-19 and clinical hematology topics.
- Data Summaries – ASH RC COVID-19 Registry for Hematology
- Latest COVID-19 Resources from ASH Publications:
- Webinar: Town Hall on NIH-organized Trials of Antithrombotic Agents in Patients with COVID-19: Hear the Latest and Become Involved in ACTIV-4
- Webinar: ASH Guidelines on Use of Anticoagulation in Patients with COVID-19
- Webinar: Sickle Cell Disease and COVID-19 Management in the Emergency Department
- Brigham and Women's Hospital (COVID-19 Critical Care Clinical Guidelines)
- COA (Community Oncology Alliance) (Administrator and Clinician Tools, Patient-facing materials)
- Seattle Cancer Care Alliance (patient screening and testing tools, PPE donning and doffing videos, telehealth FAQs)
- University of Washington (Screening and testing algorithms, policies and procedures)
Treatments and Prevention
- COVID-19 and Vaccines for the Immunocompromised (Version 2.1; last updated December 23, 2020)
- COVID-19 and Convalescent Plasma (Version 6.0; last updated November 30, 2020)
- COVID-19 and Aggressive Non-Hodgkin Lymphoma (Version 4.0; last updated November 30, 2020)
- COVID-19 and Acute Lymphoblastic Leukemia - Adult (Version 2.0; last updated November 24, 2020)
- COVID-19 and Acute Lymphoblastic Leukemia - Pediatric (Version 2.1; last reviewed November 30, 2020)
- COVID-19 and Acute Myeloid Leukemia (Version 1.4; last updated November 18, 2020)
- COVID-19 and Chronic Lymphocytic Leukemia (Version 4.0; last updated November 17, 2020)
- COVID-19 and Chronic Myeloid Leukemia (Version 2.0; last reviewed January 4, 2021)
- COVID-19 and Hematopoietic Cell Transplantation (Version 1.1; last updated October 6, 2020)
- COVID-19 and Hodgkin Lymphoma (Version 4.0; last updated November 30, 2020)
- COVID-19 and Indolent Lymphomas (Version 4.0; last updated November 30, 2020)
- COVID-19 and Myelodysplastic Syndromes (Version 4.0; last updated November 17, 2020)
- COVID-19 and Myeloproliferative Neoplasms (Version 6.0; last updated January 4, 2021)
- COVID-19 and Multiple Myeloma (Version 2.0; last updated November 17, 2020)
- COVID-19 and Aplastic Anemia (Version 2.0; last updated November 30, 2020)
- COVID-19 and Coagulopathy (Version 6.0; last updated December 24, 2020)
- COVID-19 and Immune Thrombocytopenic Purpura (Version 5.0; last reviewed November 18, 2020)
- COVID-19 and Pulmonary Embolism (Version 4.0; last updated December 24, 2020)
- COVID-19 and Sickle Cell Disease (Version 5.0; last updated September 22, 2020)
- COVID-19 and Thalassemia (Version 2.0; last reviewed September 22, 2020)
- COVID-19 and Thrombotic Thrombocytopenic Purpura (Version 3.0; last reviewed November 14, 2020)
- COVID-19 and VTE/Anticoagulation (Version 7.0; last updated December 24, 2020)
Clinical Laboratory Topics
- COVID-19 and aPL Antibodies (Version 1.0; last updated April 20, 2020)
- COVID-19 and D-dimer (Version 1.0; last updated April 20, 2020)
- COVID-19 and Viscoelastic Hemostasis Assays (Version 1.0; last updated May 11, 2020)
Clinical FAQ Resources from Other Societies
- Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity
- Information about ECMO from ELSO
- ISA recommendations on the management of patients with systemic amyloidosis during the COVID-19 pandemic
Guidance About COVID-19 Treatment
- SCD Patients Presenting to the Emergency Department During the COVID-19 Pandemic: Considerations and a Checklist
- Assessment of Evidence for COVID-19 related treatments
- Tables of COVID-19 drug-drug interactions
- NIH COVID treatment guidance
- COVID Ready Communication Skills: A playbook of VitalTalk Tips
- CDC Clinician On-Call Center
24-hour access to CDC clinicians to answer COVID-19 questions.
Clinical Trials and Studies
- ASH RC COVID-19 Registry for Hematology
The ASH Research Collaborative’s (ASH RC) Data Hub is capturing data on people who test positive for COVID-19 and have been or are currently being treated for a hematologic condition. As data are received, near real-time observational data summaries are reported for clinicians on the front line of the COVID-19 pandemic. Clinicians and other health care providers worldwide are invited to enter de-identified data on all confirmed COVID-19 cases for hematology patients, regardless of recovery or active treatment status. Online data entry takes approximately 5 minutes to complete.
- Secure-SCD Registry (Medical College of Wisconsin)
This registry is designed to capture pediatric and adult COVID-19 cases that are occurring across the world in patients living with sickle cell disease.
- CCC19 (COVID-19 and Cancer Consortium)
A consortium of over 100 cancer centers and other organizations who have come together to collect data about cancer patients who have been infected with COVID-19.
- AMA Physician Guide to Keeping Your Practice Open
- CMS Guidance on re-opening facilities to non-COVID care
- ASCO guide to cancer care delivery during COVID
American Society of Hematology
- ASH Policy Resources
- ASH Summary of the Coronavirus Aid, Relief and Economic Security (CARES) Act
- Latest COVID-19 Resources from ASH Publications
- Interim Guidelines for COVID-19 Management
- Guidance for BMT Center Functioning During COVID-19 Pandemic
EHA (European Hematology Association)
New England Journal of Medicine
Journal of Thrombosis and Haemostasis
British Journal of Haematology
- Coronavirus Tech Handbook (manual for front-line providers)
American Society of Hematology
- ASH COVID-19 Research Agenda for Hematology
- Summary of NIH Guidance on Grants, Operations During COVID-19 Response
- FDA Issues Emergency Use Authorization for Pfizer-BioNTech COVID-19 Vaccine
- FDA statistical considerations for clinical trials during COVID
- FDA Guidance on Clinical Trials
- FDA issues guidance on emergency INDs for convalescent plasma for COVID-19
- COVID-19 Seroprevalence Studies Hub
CDC and NIH have developed the COVID-19 Seroprevalence Studies Hub to provide an interactive dashboard to compare COVID19 serology studies across the country.
- Summary of NIH ACTIV trials: Accelerating COVID-19 therapeutic interventions and vaccines
- NOSI from NIAID for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV02 – expires 9/1/2021
- COVID-19: Information for NIH Applicants and Recipients of NIH Funding
- LitCovid: a curated literature hub by NLM
This hub tracks up-to-date scientific information about COVID-19. Articles are updated daily and are categorized by different research topics and geographic locations.
- Blood and Bone Seminar
Dr. Kellie Machlus from Harvard Medical School and Brigham and Women’s Hospital has organized this seminar series to continue scientific education during this time of travel restrictions and meeting cancellations.
- Connecting the Scientific Community Seminar Series
Drs. Kornelia Polyak and David Weinstock from Dana-Farber/Harvard Cancer Center have organized this seminar series (12:00 pm Eastern every Tuesday and Thursday) to facilitate scientific exchanges during the COVID-19 restrictions.
Frequently Asked Questions
- COVID-19 and Trainees: General Information (Version 1.1; last updated October 6, 2020)
- COVID-19 and Fellows (Version 1.1; last updated October 6, 2020)
- COVID-19 and Postdoctorate Students (Version 1.1; last updated October 6, 2020)
- COVID-19 and Residents (Version 1.1; last updated October 6, 2020)
Is there a hematology-related COVID-19 resource that has been helpful to you that is not listed here? Is there content here that's inappropriate or outdated? Are there additional topics you would like to see addressed on this site? We welcome your feedback below.